| Symbol | AORT |
|---|---|
| Name | ARTIVION, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 1655 ROBERTS BOULEVARD NORTH WEST, KENNESAW, Georgia, 30144, United States |
| Telephone | +1 770 419-3355 |
| Fax | — |
| — | |
| Website | https://www.artivion.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Artivion is a leader in the manufacturing processing and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple elegant solutions that address cardiac and vascular surgeons most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseasescoupled with our recent acquisitions and partnershipshave empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts surgical sealants prosthetic heart valves and aortic stents and stent-grafts. Artivion has over 1250 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta Georgia Austin Texas and Hechingen Germany. Additional info from NASDAQ: |
New Form ARS - ARTIVION, INC. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001999371-26-007513 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - ARTIVION, INC. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001999371-26-007512 <b>Size:</b> 403 KB
Read moreNew Form DEF 14A - ARTIVION, INC. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001999371-26-007510 <b>Size:</b> 3 MB
Read moreNew Form SCHEDULE 13G/A - ARTIVION, INC. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000681 <b>Size:</b> 7 KB
Read moreHorton Amy 🟡 adjusted position in 6.6K shares of ARTIVION, INC. (AORT) at $37.78 Transaction Date: Mar 02, 2026 | Filing ID: 014898
Read moreHolloway Jean F 🟡 adjusted position in 15.0K shares of ARTIVION, INC. (AORT) at $38.00 Transaction Date: Mar 02, 2026 | Filing ID: 014896
Read moreStanton Marshall S. 🟡 adjusted position in 19.7K shares of ARTIVION, INC. (AORT) at $37.78 Transaction Date: Mar 02, 2026 | Filing ID: 014894
Read moreDavis John E 🟡 adjusted position in 24.3K shares of ARTIVION, INC. (AORT) at $37.78 Transaction Date: Mar 02, 2026 | Filing ID: 014892
Read moreBerry Lance A 🟡 adjusted position in 34.6K shares of ARTIVION, INC. (AORT) at $37.78 Transaction Date: Mar 02, 2026 | Filing ID: 014890
Read moreMackin James P 🟡 adjusted position in 99.1K shares of ARTIVION, INC. (AORT) at $37.78 Transaction Date: Mar 02, 2026 | Filing ID: 014887
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07413926 | Mitral Valve Repair With the Chord-X System: A Long Term Evaluation | — | Mitral Regurgitation (MR) | Not_Yet_Recruiting | 2026-06-01 | 2034-06-01 | ClinicalTrials.gov |
| NCT05314868 | Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in… | — | Congenital Heart Disease | Terminated | 2022-03-31 | 2022-11-30 | ClinicalTrials.gov |
| NCT04142658 | PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can … | Phase3 | Aortic Valve Disease | Terminated | 2020-05-01 | 2022-12-12 | ClinicalTrials.gov |
| NCT03035643 | DARTS I Feasibility Study | Na | Aortic Dissection | Completed | 2017-03-05 | 2024-03-19 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Chord-X system implant | DEVICE | Preclinical | Mitral Regurgitation (MR) | NOT_YET_RECRUITING | NCT07413926 |
| Arcevo™ LSA Hybrid Stent Graft System | DEVICE | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| On-X Aortic Mechanical Valve | DEVICE | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Warfarin | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 2.5 MG | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 5 MG | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| PhotoFix | DEVICE | Preclinical | Congenital Heart Disease | TERMINATED | NCT05314868 |
| AMDS | DEVICE | Approved | Acute Aortic Dissection | ACTIVE_NOT_RECRUITING | NCT05174767 |
| Arista AH | DEVICE | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |
| PerClot Polysaccharide Hemostatic System | DEVICE | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |